Drug Trial Radar · NCT07481734
Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Feb 2, 2026
Primary completion
Feb 14, 2027
Study completion Feb 17, 2028
Sponsor
- Lead sponsor
- Hudson BiotechIndustry
- Sponsor type
- Industry
- First posted
- Mar 19, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized, double-blind, placebo-controlled Phase II study evaluates whether daily subcutaneous tesamorelin (a growth hormone-releasing hormone analog) reduces liver fat in adults with fatty liver disease. Participants receive tesamorelin or matching placebo for 52 weeks, with standardized lifestyle counseling in both groups. Liver fat is quantified by MRI-proton density fat fraction (MRI-PDFF). Key safety monitoring includes glucose metrics and IGF-1.
Conditions
- Metabolic Associated Steatotic Liver Disease
- Nonalcoholic Steatohepatitis
- Hepatic Steatosis
Interventions
TesamorelinDrug
for injection, 2 mg SC once daily; participant self-administration after training. Dose may be reduced to 1 mg daily if IGF-1 z-score meets protocol threshold.
PlaceboDrug
for injection (mannitol-based, identical appearance), SC once daily.
Standardized lifestyle counselingBehavioral
dietary guidance and physical activity recommendations,delivered at baseline and reinforced at each visit.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in hepatic fat fraction by MRI-PDFF (percentage points)Time frame: 52 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University Shenzhen Hospital
Shenzhen, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.